Download PDF
1 / Pages

Other users also viewed these articles

Evaluation of clinical events and costs associated with the addition of dapagliflozin to chronic kidney disease treatment: Cost offset analysis Juan Francisco Navarro-González; Alberto Ortiz; Ana Cebrián Cuenca; Lluís Segú; Belén Pimentel; Unai Aranda; Blanca Lopez-Chicheri; Margarita Capel; Elisenda Pomares Mallol; Christian Caudron; Juan José García Sánchez; Roberto Alcázar Arroyo;
Nefrologia (English Version). 2024;44:857-67
Association of aortic stiffness with abdominal vascular and coronary calcifications in patients with stage 3 and 4 chronic kidney disease Juan Carlos Hidalgo Santiago; Jary Perelló Martínez; Javier Vargas Romero; José Luis Pallares; Alfredo Michan Doña; Pablo Gómez-Fernández;
Nefrologia (English Version). 2024;44:256-67
Etelcalcetide controls secondary hyperparathyroidism and raises sclerostin levels in hemodialysis patients previously uncontrolled with cinacalcet Luciano Artur Lopes Pereira; Catarina Meng; Manuel Augusto Gonçalves Amoedo; Maria Teresa de Sousa Costa Pinto Ferreira Mendes; Marco Alexandre Mateus Prazeres Marques; João Miguel Machado Dória Frazão; André Luiz Loureiro Weigert;
Nefrologia (English Version). 2023;43:197-203